| CIBCX | GBLEX | CIBCX / GBLEX | |
| Total Expense Ratio | 1.33 | 0.85 | 156% |
| Annual Report Gross Expense Ratio | 1.33 | 0.85 | 156% |
| Fund Existence | 25 years | 15 years | - |
| Gain YTD | 9.084 | 5.827 | 156% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 250 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 128B | 33.1B | 387% |
| Annual Yield % from dividends | 2.02 | 1.97 | 102% |
| Returns for 1 year | 9.50 | 7.35 | 129% |
| Returns for 3 years | 36.37 | 26.93 | 135% |
| Returns for 5 years | 35.45 | 15.49 | 229% |
| Returns for 10 years | 60.58 | 55.08 | 110% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBTDX | 173.26 | N/A | N/A |
| Franklin Biotechnology Discovery C | |||
| DEVIX | 80.92 | N/A | N/A |
| Nomura Small Cap Value Institutional | |||
| RGBGX | 42.28 | -0.01 | -0.02% |
| American Funds Global Balanced R-6 | |||
| FEMAX | 15.41 | -0.06 | -0.39% |
| First Eagle U.S. SMID Cap Opportunity A | |||
| VALLX | 44.40 | -0.81 | -1.79% |
| Value Line Larger Companies Focused Inv | |||